Health Economic Evidence for Liquid- and Tissue-based Molecular Tests that Inform Decisions on Prostate Biopsies and Treatment of Localised Prostate Cancer: A Systematic Review
Open Access
- 26 March 2021
- journal article
- review article
- Published by Elsevier BV in European Urology Open Science
- Vol. 27, 77-87
- https://doi.org/10.1016/j.euros.2021.03.002
Abstract
No abstract availableFunding Information
- Movember Foundation
This publication has 47 references indexed in Scilit:
- Contemporary Use of Initial Active Surveillance Among Men in Michigan with Low-risk Prostate CancerEuropean Urology, 2015
- A Framework to Evaluate the Cost-Effectiveness of the NADiA ProsVue Slope to Guide Adjuvant Radiotherapy among Men with High-Risk Characteristics Following Prostatectomy for Prostate CancerValue in Health, 2014
- Systematic Review and Quality Assessment of Cost-Effectiveness Analysis of Pharmaceutical Therapies for Advanced Colorectal CancerAnnals of Pharmacotherapy, 2013
- Impact of adoption of a decision algorithm including PCA3 for repeat biopsy on the costs for prostate cancer diagnosis in FranceJournal of Medical Economics, 2012
- Urinary proteome analysis for prostate cancer diagnosis: Cost‐effective application in routine clinical practice in GermanyInternational Journal of Urology, 2011
- The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and ElaborationPLoS Medicine, 2009
- Mortality Results from a Randomized Prostate-Cancer Screening TrialThe New England Journal of Medicine, 2009
- Screening and Prostate-Cancer Mortality in a Randomized European StudyThe New England Journal of Medicine, 2009
- Cost-Effectiveness of Percent Free PSA for Prostate Cancer Detection in Men with a Total PSA of 4–10 ng/mlUrologia Internationalis, 2007